Employees: 466
Size Sun Pharma Advanced Research (SPARC.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $660M, the 751st largest of 1,066 India companies the cockpit tracks. Shares closed at ₹190.12 on 18 Nov 2026.
Performance Over six months the shares gained 5.8%, against -14.2% for the median peer and +3.8% for the India market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 3,141.0% over the last twelve months (peer median +8.6%); the operating margin is 84.3% (peer median 10.0%).
Valuation It trades at 2.5× enterprise value to sales against a peer median of 2.7× (9th cheapest of 17).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹19.3B | ₹18.8B | ₹718M | ₹755M | ₹2.39B |
| Revenue growth | — | +2,518% | -5% | -68% | — |
| Gross profit | ₹17.8B | ₹17.1B | -₹1.34B | -₹1.24B | ₹821M |
| EBITDA | ₹16.4B | ₹16.1B | -₹3.22B | -₹3.99B | -₹2.12B |
| Net income | ₹16.4B | ₹15.5B | -₹3.43B | -₹3.87B | -₹2.23B |
| Free cash flow | n/a | -₹2.97B | -₹3.65B | -₹4.35B | -₹904M |
| Capital expenditure | n/a | ₹238M | ₹103M | ₹265M | ₹154M |
| Total debt | ₹24.4M | ₹5.59B | ₹2.69B | ₹612M | ₹157M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SPARC.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.7% | -5.2% | 4th highest of 21 |
| 6-month return | +5.8% | -14.2% | 5th highest of 21 |
| Distance from 52-week high | -34.2% | -38.7% | 10th highest of 21 |
| Revenue growth (TTM) | +3,141.0% | +8.6% | highest of 17 |
| Operating margin | 84.3% | 10.0% | highest of 17 |
| EV / Sales | 2.5× | 2.7× | 9th cheapest of 17 |
| EV / EBITDA | 3.0× | 9.4× | 3rd cheapest of 8 |
| Net debt / EBITDA | -0.8× | -1.3× | 4th most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sun Pharma Advanced Research SPARC.NS | India | $660M | +6% | +3,141% | 84% | 2.5× | n/a | n/a |
| FDC FDC.NS | India | $653M | +3% | +10% | 14% | 2.4× | 25.2% | +10.3% |
| Annexon ANNX | United States | $671M | -30% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $672M | -35% | +7% | 8% | 6.7× | 31.9% | +19.8% |
| Philogen PHIL.MI | Italy | $672M | -11% | +295% | 79% | 0.9× | n/a | n/a |
| Youcare Pharmaceutical 688658.SS | China | $674M | -49% | -7% | -13% | 1.7× | n/a | n/a |
| Innova Captab INNOVACAP.NS | India | $645M | +20% | +37% | 12% | 3.4× | 27.1% | +31.4% |
| Yabao Pharmaceutical 600351.SS | China | $678M | 0% | -3% | 16% | 1.6× | -8.3% | -2.8% |
| Hainan Haiyao 000566.SZ | China | $642M | -18% | -18% | -50% | 10.6× | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $641M | -19% | +23% | 11% | 3.0× | 9.1% | +7.9% |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | 12.8× | 36.3% | +16.2% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -31% | -36% | 36% | 2.5× | n/a | n/a |
| Earth 4985.T | Japan | $687M | +7% | +4% | 4% | 0.5× | -1.6% | -1.8% |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | 16.9× | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | 1.6× | n/a | n/a |
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| Bicara Therapeutics BCAX | United States | $623M | -54% | n/a | n/a | n/a | n/a | n/a |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | 0.6× | 4.0% | +5.3% |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $619M | -10% | +13% | 4% | 5.3× | n/a | n/a |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 3.0× | -8.7% | +8.8% |